Galatea Bio

In August 2024, HDV invested in Galatea Bio, a biotechnology company with the mission to enable precision health at scale for all by leveraging AI and genomics.

Founded in 2021, Galatea Bio is addressing the critical unmet need for large-scale diverse data, with a unique focus on generating actionable genetic insights on underrepresented populations in the US, Latin America, Africa, and Asia.

The company has established a diversified global biopharma data platform integrating ancestry-informed clinical diagnostics, powered by the world’s most diverse global biobank and AI-enabled products for algorithmic diagnostics and drug discovery.